Drug intelligence / Profile preview

BXT-110

Development stage: Preclinical
Lead developer: BrainXell Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intracerebral

Overview

**BXT-110** is an autologous induced pluripotent stem cell (iPSC)-derived neuronal cell therapy developed by BrainXell Therapeutics for Parkinson's disease. It consists of midbrain dopaminergic progenitor cells (mDAPs) generated from patient-derived iPSCs, designed to replace lost dopaminergic neurons in the substantia nigra, restoring dopamine production to improve motor control, mood, and cognitive functions. Preclinical data show >75% FOXA2+/OTX2+ expression, >60% TH+ neurons in vitro, significant graft survival (>60%) and functional recovery in 6-OHDA rodent models as early as 12 weeks post-transplantation, sustained up to 6 months, supporting its potential as a disease-modifying regenerative therapy.[1][2][4][7][10]

Beyond the preview

Go deeper on BXT-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BXT-110.

Explore the full profile